PERCEPTIVE ADVISORS LLC - 09 Mar 2026 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: SLDB
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 16:00:03 UTC
Prior SEC filing: 02 Jan 2026
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member

Key filing fact

PERCEPTIVE ADVISORS LLC filed Form 4 for Solid Biosciences Inc. (SLDB) on 11 Mar 2026.

Key facts

This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Solid Biosciences Inc. (SLDB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2026, 16:00.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001224962 Primary reporting owner

PERCEPTIVE ADVISORS LLC

Relationship: Director, 10%+ Owner
Address: 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
Signature: /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Signature date: 11 Mar 2026

CIK 0001164426

EDELMAN JOSEPH

Relationship: Director, 10%+ Owner
Address: 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
Signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Signature date: 11 Mar 2026

CIK 0001249675

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

Relationship: Director, 10%+ Owner
Address: 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
Signature: /s/ Joseph Edelman
Signature date: 11 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLDB transaction Derivative

Pre-Funded Warrant (right to buy)

Award

Transaction value
Shares: +8,912,655
Change %
Price: $5.61^*
Shares after: 8,912,655
Date: 09 Mar 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 8,912,655
Exercise price: $0.001000
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund (as defined herein) to exercise any of its Warrants.

Footnote F2

The Pre-Funded Warrants do not expire.

Footnote F3

The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor.

Footnote F4

Each of Mr. Edelman, the Advisor, and the Master Fund disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.